Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
CA 2384413 A1 · Owner: Robl, James · Inventors: Robl, James; Stice, Steven L.; Cibelli, Jose
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells in , particular human isogenic embryonic or stem cells. These embryonic or stemlike cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes e.g. at specific , sites of the genome of such cells by homologous recombination. These cells which may contain a heterologous gene, are especially useful in cell transplantation therapied and for in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 14, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 14, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 14, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.